Kasvu Therapeutics
Helsinki, Finland
◆ Total Raised
$34.4M
◆ Stage
series-a
◆ Location
Helsinki, Finland
◆ Founded
2023
◆ Team size
1-10
◆ Links
◆ About Kasvu Therapeutics
Finnish biotech developing a TrkB-targeting small molecule antidepressant designed to replicate psychedelic neuroplasticity benefits without hallucinogenic effects.
◆ What sets it apart
It targets TrkB directly with a selective small molecule designed to deliver rapid, long-lasting antidepressant effects without hallucinogenic side effects.
◆ Sectors
◆ Business
Modelbiotech
CustomerBiopharma partners, clinicians, and ultimately patients with major depressive disorder and other neuropsychiatric disorders
◆ Notable
- Raised €30 million Series A led by Hadean Ventures on 2026-09-24
- Advanced lead program KTX-0141 toward IND/CTA-enabling studies and planned clinical development
- Described as a University of Helsinki spinout
◆ Backing funds on Raise
- NSI Nordic Science Iseries-a
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Kasvu Therapeutics do?
Finnish biotech developing a TrkB-targeting small molecule antidepressant designed to replicate psychedelic neuroplasticity benefits without hallucinogenic effects.
Where is Kasvu Therapeutics based?
Kasvu Therapeutics is based in Helsinki, Finland, founded in 2023.
How much has Kasvu Therapeutics raised?
Kasvu Therapeutics has raised $34.4M in tracked funding and is currently at the series-a stage.
Who has invested in Kasvu Therapeutics?
Investors in Kasvu Therapeutics include Hadean Ventures, Tesi, Innovestor Life Science Fund, Nordic Science Investments, Finnish Drug Discovery Center Ltd, Stephen Industries and University of Helsinki Funds.